Illumina launched plans for BioInsight, a data‑focused business unit that will produce and monetize sequencing‑intensive datasets for pharma customers, positioning the company to sell data and analysis alongside instruments. CEO Jacob Thaysen said the approach will let Illumina shoulder costly experiments such as Perturb‑seq and repackage data for AI model training and foundation biology efforts. Separately, Terray Therapeutics announced a discovery milestone with Bristol Myers Squibb under a multi‑target collaboration, showing its Experimentation Meets Machine Intelligence (EMMI) platform can deliver compounds against novel, difficult targets. Terray’s tArray hardware and large‑scale binding dataset underpin its ability to explore chemical space beyond existing patents—moves that highlight data and AI becoming strategic assets in small‑molecule discovery.